|本期目录/Table of Contents|

[1]文师俊,张运欢,李程远.PS联合双水平持续正压通气治疗NRDS早产儿的临床分析[J].中华肺部疾病杂志,2020,(06):755-759.[doi:10.3877/cma.j.issn.1674-6902.2020.06.008]
　Wen Shijun,Zhang Yunhuan,Li Chengyuan..Value of PS combined with bi-level continuous positive airway pressure in the treatment of preterm infants with NRDS[J].,2020,(06):755-759.[doi:10.3877/cma.j.issn.1674-6902.2020.06.008]
点击复制

PS联合双水平持续正压通气治疗NRDS早产儿的临床分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2020年06期
页码:
755-759
栏目:
论著
出版日期:
2020-12-20

文章信息/Info

Title:
Value of PS combined with bi-level continuous positive airway pressure in the treatment of preterm infants with NRDS
作者:
文师俊; 张运欢; 李程远
436000 湖北省鄂州市中心医院新生儿科
Author(s):
Wen Shijun;  Zhang Yunhuan;  Li Chengyuan.
Department of Neonatology, Ezhou Central Hospital, Ezhou 436000 China
关键词:
新生儿呼吸窘迫综合征;  肺表面活性物质;  早产儿;  氧合;  双水平气道正压通气
Keywords:
Neonatal respiratory distress syndrome;  Pulmonary surfactant;  Preterm infant;  Oxygenation;  Bi-level continuous positive airway pressure
分类号:
-
DOI:
10.3877/cma.j.issn.1674-6902.2020.06.008
摘要:
目的 分析肺表面活性物质(PS)联合双水平持续气道正压通气(CPAP)治疗新生儿呼吸窘迫综合征(NRDS)早产儿的效果及对患儿肺氧合、肺泡灌洗液B细胞淋巴瘤基因-2(Bcl-2)、半胱氨酸天冬氨酸蛋白酶-3(Caspase-3)、转化生长因子-β1(TGF-β1)的影响。方法 回顾性分析2016年2月至2019年3月医院新生儿重症监护病房(NICU)收治的99例NRDS早产儿的临床资料,按治疗方式分为A组56例(PS+双水平CPAP)、B组43例(PS+常规CPAP),比较两组患儿无创呼吸支持不同时间肺氧合功能的变化,记录无创通气时间、氧支持时间、住院时间、PS应用情况、气管插管率及相关并发症发生情况,测定肺泡灌洗液Bcl-2、Caspase-3、TGF-β1表达情况。结果 A组上机12、24 h动脉血二氧化碳分压(PaCO2)低于B组,上机12 h 动脉血氧分压(PaO2)高于B组,上机12、24、48 h吸入氧浓度(FiO2)均低于B组,上机12 h氧合指数(OI)高于B组(P<0.05); A组氧支持时间短于B组,气管插管率、总并发症发生率低于B组(P<0.05); 上机48 h,A组Caspase-3、TGF-β1低于B组,Bcl-2高于B组(P<0.05)。结论 PS联合双水平CPAP治疗NRDS早产儿安全有效,可快速改善患儿肺氧合功能,减轻肺泡炎症及氧化损伤,缩短氧暴露时间,降低呼吸机相关并发症发生风险。
Abstract:
Objective To analyze curative effect of pulmonary surfactant(PS)combined with bi-level continuous positive airway pressure(CPAP)on preterm infants with neonatal respiratory distress syndrome(NRDS)and their influences on pulmonary oxygenation and expression of B cell lymphoma-2(Bcl-2), cysteine-asparticacidprotease-3(Caspase-3)and transforming growth factor-β1(TGF-β1)in bronchoalveolar lavage fluid(BALF). Methods The clinical data of 99 NRDS preterm infants who were admitted to neonatal intensive care unit(NICU)of the hospital from February 2016 to March 2019 were retrospectively collected. According to different treatment methods, they were divided into group A(PS + bi-level CPAP, 56 cases)and group B(PS + routine CPAP, 43 cases). The changes of pulmonary oxygenation function under non-invasive respiratory support for different time were compared between the two groups. The non-invasive ventilation time, oxygen support time, hospitalization time, PS usage, tracheal intubation rate and occurrence of related complications were recorded. The expression of Bcl-2, Caspase-3 and TGF-β1 in BALF was measured. Results After 12 h and 24 h of starting ventilation, arterial partial pressure of carbon dioxide(PaCO2)of group A was lower than that of group B. After 12 h of starting ventilation, arterial partial pressure of oxygen(PaO2)of group A was higher than that of group B. After 12 h, 24 h and 48 h of starting ventilation, fraction of inspired oxygen(FiO2)in group A was lower than that in group B. After 12 h of starting ventilation, oxygenation index(OI)in group A was higher than that in group B(P<0.05). The oxygen support time of group A was shorter than that of group B, tracheal intubation rate and total incidence of complications were lower than those of group B(P<0.05). After 48 h of starting ventilation, Caspase-3 and TGF-β1 in group A were lower than those in group B, while Bcl-2 was higher than that in group B(P<0.05). Conclusion It is safe and effective of PS combined with bi-level CPAP in treatment of preterm infants with NRDS. It can rapidly improve pulmonary oxygenation function, alleviate alveolar inflammation and oxidative damage, shorten oxygen exposure time, and reduce risks of ventilator-related complications.

参考文献/References:

1 蔡金标, 马 进, 张立霞. PS(固尔苏)分别联合BiPAP、NCPAP对新生儿呼吸窘迫综合征疗效对比观察[J]. 解放军预防医学杂志, 2019, 37(8): 183-184,186.
2 吴淑明, 郭淑艳, 赵 旭. 肺表面活性物质联合持续气道正压通气治疗新生儿呼吸窘迫综合征的效果研究[J]. 中国妇幼保健, 2017, 32(17): 4174-4176.
3 荣 箫, 周 伟, 赵小朋, 等. 微创肺表面活性物质治疗在新生儿呼吸窘迫综合征中的疗效与安全性[J]. 中华实用儿科临床杂志, 2018, 33(14): 1071-1074.
4 卢维城, 魏海波, 陈有平. 经胃管微创注入肺表面活性物质在新生儿呼吸窘迫综合征中的应用[J]. 广东医学, 2016, 37(21): 3233-3235.
5 淡 云, 王亚萍. 双水平气道及经鼻持续气道正压通气联合肺泡表面活性物质治疗早产儿呼吸窘迫综合征疗效观察[J]. 安徽医药, 2016, 20(5): 957-958.
6 Chen C, Tian T, Liu L, et al. Gender-related efficacy of pulmonary surfactant in infants with respiratory distress syndrome: A STROBE compliant study[J]. Medicine, 2018, 97(17): e0425-e0425.
7 Kallio M, Koskela U, Peltoniemi O, et al. Neurally adjusted ventilatory assist(NAVA)in preterm newborn infants with respiratory distress syndrome-a randomized controlled trial[J]. Eur J Pediatr, 2016, 175(9): 1175-1183.
8 金汉珍, 黄德琅, 官希吉, 主编. 实用新生儿学(第3版)[M]. 北京: 人民卫生出版社, 2003: 87-91.
9 蔡志勇, 刘进娣, 卞洪亮, 等. 不同时间应用“气管插管-使用肺表面活性物质-拔管使用持续呼吸道正压通气”技术在呼吸窘迫综合征高危早产儿中的疗效[J]. 中华实用儿科临床杂志, 2016, 12(2): 101-104.
10 Santos A, Lucchetta L, Monge-Garcia M, et al. The Open Lung Approach Improves Pulmonary Vascular Mechanics in an Experimental Model of Acute Respiratory Distress Syndrome[J]. Crit Care Med, 2017, 45(3): e298-e305.
11 Braide-Moncoeur O, Tran NT, Long JR, et al. Peptide-based synthetic pulmonary surfactant for the treatment of respiratory distress disorders[J]. Pediatr Pulmonol, 2016, 32: 22-28.
12 Alkan Ozdemir S, Arun Ozer E, Ilhan O, et al. Impact of targeted-volume ventilation on pulmonary dynamics in preterm infants with respiratory distress syndrome[J]. Pediatr Pulmonol, 2017, 52(2): 213-216.
13 Chen L, Chen GQ, Shore K, et al. Implementing a bedside assessment of respiratory mechanics in patients with acute respiratory distress syndrome[J]. Crit Care, 2017, 21(1): 84-84.
14 Hagawane TN, Gaikwad RV, Kshirsagar NA. Dual hit lipopolysaccharide & oleic acid combination induced rat model of acute lung injury/acute respiratory distress syndrome[J]. Indian J Med Res, 2016, 143(5): 624-632.
15 李建业, 刘 伟, 张彦伦. INSURE策略与机械通气治疗新生儿呼吸窘迫综合征疗效对照分析[J]. 中国医师杂志, 2016, 18(2): 273-275.
16 Villar J, Martínez D, Mosteiro F, et al. Is Overall Mortality the Right Composite Endpoint in Clinical Trials of Acute Respiratory Distress Syndrome?[J]. Crit Care Med, 2018, 46(6): 892-899.
17 Summers C, Singh NR, Worpole L, et al. Incidence and recognition of acute respiratory distress syndrome in a UK intensive care unit[J]. Thorax, 2016, 71(11): 1050-1051.
18 林 梅, 朱晓波, 薛 江. 肺表面活性物质联合不同通气方式对重症新生儿呼吸窘迫综合征的效果分析[J]. 中国儿童保健杂志, 2019, 27(5): 561-564.
19 McKown AC, McGuinn EM, Ware LB, et al. Preadmission Oral Corticosteroids Are Associated With Reduced Risk of Acute Respiratory Distress Syndrome in Critically Ⅲ Adults With Sepsis[J]. Crit Care Med, 2017, 45(5): 774-780.
20 迟 明, 梅亚波. 新生儿急性呼吸窘迫综合征研究进展[J]. 中国当代儿科杂志, 2018, 20(9): 724-728.
21 邱建武, 刁诗光, 刘晓燕, 等. 外源性肺表面活性物质对新生儿呼吸窘迫综合征患儿免疫功能的影响[J]. 中国儿童保健杂志, 2018, 26(6): 619-621, 633.
22 Hsu CF, Cheng JS, Lin WC, et al. Electrical impedance tomography monitoring in acute respiratory distress syndrome patients with mechanical ventilation during prolonged positive end-expiratory pressure adjustments[J]. J Formos Med Assoc, 2016, 115(3): 195-202.
23 钱文亚. 外源性肺表面活性物质治疗新生儿呼吸窘迫综合征研究进展[J]. 临床儿科杂志, 2018, 36(6): 476-479.

备注/Memo

备注/Memo:
基金项目: 湖北省自然科学基金资助项目(2016CFB592)
通信作者: 张运欢, Email: 2465733471@qq.com
更新日期/Last Update: 2020-12-20